However, in clinical infection lung disease, considering that TJ-5 may indeed promote infection due to its systemic MyD88 inhibition, according to clinical experience, antibiotics should be given concurrently for anti-infective treatment when TJ-5 is required to suppress inflammation in infectious diseases [61,62]. This evidence concerns the gene MYD88 and infection.